Evaluation of Abuse Potential of Synthetic Cannabinoids and Phytocannabinoids Using In Vivo Pharmacological Studies

Closed Solicitation Posted

Solicitation number
15DDHQ25Q00000010
Agency
Responses due
Set-aside
No set-aside

Opportunity facts

Place of performance
United States

Notice details come from SAM.gov. Updated .

About this opportunity

The Drug Enforcement Administration (DEA) is seeking a contractor to conduct comprehensive in vivo pharmacological studies evaluating the abuse potential of synthetic cannabinoids and phytocannabinoids. The solicitation (RFQ 15DDHQ25Q00000010) requires a qualified research institution to perform specialized scientific assessments including locomotor activity assays, drug discrimination studies, and cannabinoid tetrad studies on various test substances. Contractors must possess a Schedule I researcher registration and demonstrate capability to obtain necessary test drugs, conduct rodent-based studies, and provide detailed investigational reports. The DEA will evaluate quotes using a best value trade-off approach, with non-price technical factors being significantly more important than cost considerations. Quotes are due by April 8, 2025, with potential bidders required to submit detailed personnel qualifications, transition plans, management approaches, and past performance examples.

The solicitation is not set aside for any specific business category and is open to organizations within NAICS codes including Colleges, Universities, Medical Laboratories, Research and Development, and Testing Laboratories. The contract covers a base period from May 1, 2025, to April 30, 2026, with four additional one-year option periods extending potentially through May 1, 2029. Each ordering period involves testing 17 total drugs (15 test drugs and 2 reference drugs) across multiple assay types, with specific focus on synthetic opioids in the first period and hallucinogenic substances in subsequent periods. The place of performance is within the United States, and contractors will be responsible for purchasing reference and test substances, performing preclinical studies, and providing comprehensive documentation to the DEA. While specific award values are not explicitly stated, the solicitation includes detailed pricing templates for contractors to complete, indicating a structured approach to cost proposal submission.

Notice text

Investigational study results and a description of the methodology used to conduct the investigation in the form of a study report based on the timeline specified in the statement of work (SOW) for RFQ 15DDHQ25Q00000010

Files

File Type Posted
15DDHQ25Q00000010 Amendment 0001 03192025.pdf PDF
Pricing Sheet Templalte.xlsx XLSX spreadsheet
RFQ 15DDHQ25Q00000010.pdf PDF
PRICING SHEET TEMPLATE - Attachment 1.xlsx XLSX spreadsheet
Sample BPA Call Order - Attachment 2.xlsx XLSX spreadsheet

Similar open opportunities

Opportunity Agency Set-aside Responses due
Synthesis and Distribution of Drugs of Abuse and Related Compounds NAICS 541715 National Institute on Drug Abuse No set-aside
Synthesis and Distribution of Drugs of Abuse and Related Compounds NAICS 541715 National Institute on Drug Abuse Total Small Business

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors